The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Fall 2021 RFP: Outcome Measures, 2021Development of Novel Antibodies that Facilitate the Accurate Measurement of All Forms of Alpha-synuclein Present in Biological Fluids
Study Rationale: The ability to accurately detect and quantify alpha-synuclein and its pathology-relevant variants represents a major challenge in Parkinson’s disease (PD). Different studies report...
-
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2022Inhibiting Lrrk2 Specifically in the Brain
Study Rationale: Neurodegenerative disorders such as Parkinson’s disease (PD) affect the brain. Some of the drugs designed to treat PD have unwanted side effects in the rest of the body. To minimize...
-
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2021Impact of TRPML1 Stimulation on Clinical Biomarkers and Synuclein Pathology
Study Rationale: The protein TRPML1 regulates the clearance of cellular debris, including aggregated alpha-synuclein and toxic lipids—a process that is disrupted in Parkinson’s disease (PD). We have...
-
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2022Using “Nanobodies” to Prevent Formation of Intracellular Alpha-synuclein Aggregates
Study Rationale: The aggregation of a structurally abnormal form of the protein alpha-synuclein appears to be responsible for the initiation and progression of Parkinson’s disease (PD). In previous...
-
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2022Identification and Characterization of Compounds that Regulate the Activity of the LRRK2 System
Study Rationale: Genetic mutations that lead to the activation of the enzyme LRRK2 are a major cause of inherited Parkinson's disease (PD). We have identified a protein, termed PPM1H, that counteracts...
-
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2021Establishing the Therapeutic Potential of Engineered Neural Circuits in a Preclinical Model of Parkinson’s Disease
Study Rationale: Parkinson’s disease (PD) is caused by the death of specific brain cells that connect two different regions of the brain, disrupting a neural circuit that is key for motor function. We...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.